Conclusion
Plasma cell leukemia is indeed a rare and aggressive subtype of multiple myeloma with a poor prognosis. The diagnosis can be challenging, especially in resource-limited settings where access to advanced diagnostic tools may be limited. Additionally, the lack of clear evidence for an ideal therapeutic regimen adds to the complexity of managing this condition. Despite these challenges, a meticulous clinical approach is crucial to reaching a correct diagnosis and providing appropriate care for patients with plasma cell leukemia.